Major Leadership Transitions Reshape Pharmaceutical Industry as Merck KGaA and GSK Appoint New CEOs
核心洞察
Merck KGaA appointed Kai Beckmann as CEO following Belén Garijo's departure after 15 years with the company, while also naming David Weinreich as global head of R&D and chief medical officer.
GSK concluded Emma Walmsley's eight-year tenure as CEO, appointing Luke Miels as her successor, who brings extensive experience from leadership roles at AstraZeneca, Roche, and Sanofi-Aventis.
The pharmaceutical industry experienced widespread executive changes across biotech companies, with multiple CEO transitions and senior leadership appointments spanning oncology (搜索), regenerative medicine, and rare disease therapeutics.
The pharmaceutical industry witnessed significant leadership transitions in August and September 2025, with two major pharmaceutical companies undergoing CEO changes and numerous biotech firms reshaping their executive teams.
Major CEO Transitions at Leading Pharmaceutical Companies
Merck KGaA experienced a major leadership transition as Belén Garijo stepped down as CEO at the end of September after a 15-year tenure with the company, including six years as CEO. Kai Beckmann, formerly the head of Merck's electronics business, has taken the reins as the new CEO.
Simultaneously, Merck KGaA strengthened its research capabilities by appointing David Weinreich as global head of R&D and chief medical officer. Weinreich brings a 20-year career that includes leadership roles at Regeneron, Bayer, and Amgen, with a track record of 15 approved drugs.
GSK also concluded a significant leadership era as Emma Walmsley ended her eight-year tenure as CEO. During her leadership, Walmsley oversaw the acquisition of Novartis's consumer health division and its eventual spin-out as Haleon, while marking a renewed focus on specialty medicines and vaccines. Luke Miels, previously GSK's chief commercial officer, has been appointed as her successor, bringing extensive experience from leadership roles at AstraZeneca, Roche, and Sanofi-Aventis.
Strategic Appointments at Major Pharmaceutical Companies
Sanofi appointed Dr. Marcia Kayath as chief medical officer. She was most recently SVP and global head of medical affairs at BioMarin and previously spent eight years in leadership roles at Novartis.
Bristol Myers Squibb (搜索) strengthened its oncology (搜索) leadership with the appointment of Dr. Nathan Pennell as SVP, worldwide head of medical affairs, hematology (搜索) & oncology. A board-certified medical oncologist with nearly 25 years of experience, Pennell was previously head of thoracic oncology and clinical research at the Cleveland Clinic Taussig Cancer (搜索) Center. He will now lead BMS's global oncology medical affairs programme.
Biotech Leadership Transformations
The biotech sector experienced numerous CEO transitions during this period. Johnny Cheng, currently CFO of HUTCHMED, has been named acting CEO following the departure of Dr. Weiguo Su due to health reasons. The company, which focuses on targeted therapies (搜索) and immunotherapies (搜索), will be led by Cheng during this interim period.
Dr. Jan H. Egberts has taken the helm at NeoVac, a London-based developer of RNA-LNP-based vaccines (搜索) and therapeutics. With over 25 years of experience in pharma and medtech, Egberts most recently led his own family office, Veritas Investment.
Yasir Al-Wakeel, a physician scientist and former biotech equity analyst, has joined Vesalius Therapeutics (搜索) as CEO. His background includes over $30 billion in strategic and financial transactions, as well as clinical and academic roles in the UK. Vesalius is a Flagship Pioneering company using AI to tackle common diseases.
Specialized Biotech Executive Appointments
German biotech CatalYm, focused on antibody therapies (搜索) for solid tumours (搜索) and cachexia (搜索), made a series of high-level appointments. Heike Krupka joined as chief development officer, bringing experience from senior roles at Bristol Myers Squibb (搜索), Pfizer, and Genentech/Roche. Clinton Musil was named chief financial officer and chief business officer, having previously held executive roles at several biotech firms, including ARMO Biosciences, which was acquired by Eli Lilly for $1.6 billion.
Aurion Biotech (搜索), which develops allogeneic cell therapies (搜索) for corneal endothelial disease (搜索), made two senior appointments. Andrew Torres joins as chief manufacturing officer, following leadership roles at Molecular Templates, Neoleukin Therapeutics, Regeneron, and GE Global Research. Sterling Chung was named chief regulatory and quality officer, having previously held senior roles at Neoleukin, Molecular Templates, Immatics US, Seattle Genetics, Astellas, Takeda, and Abbott.
Scientific Leadership Expansion
Several companies expanded their scientific leadership teams during this period. David Hava joined Alltrna (搜索), a Flagship Pioneering spinout focused on transfer RNA (搜索) for treatment of rare diseases (搜索), as chief scientific officer. He brings nearly 20 years of experience across rare and inflammatory diseases.
Dr. Fawzi Benzaghou joined Parabilis Medicines (搜索) as chief medical officer. He was previously SVP and global head of oncology (搜索) R&D at Ipsen, where he oversaw numerous IND submissions and several major regulatory approvals. Cambridge, Massachusetts-based Parabilis is developing novel peptide therapies (搜索) for both rare and common cancers.
Financial Leadership Changes
The industry also saw numerous chief financial officer appointments. George Eldridge joined Abcuro, bringing experience from Aerovate Therapeutics, where he led the company through its IPO and a reverse merger. Thomas Gidoin became CFO at OSE Immunotherapeutics, with a background in IPOs and cross-border financing from roles at GenSight Biologics and DBV Technologies.
These leadership changes reflect the dynamic nature of the pharmaceutical industry as companies position themselves for future growth and innovation across therapeutic areas ranging from oncology (搜索) to rare diseases (搜索) and regenerative medicine.